|1.||Bast, Aalt: 6 articles (07/2012 - 06/2004)|
|2.||Bast, A: 4 articles (02/2011 - 02/2007)|
|3.||van der Vijgh, W J F: 4 articles (02/2011 - 02/2007)|
|4.||Bruynzeel, A M E: 3 articles (10/2007 - 02/2007)|
|5.||Niessen, H W M: 2 articles (10/2007 - 03/2007)|
|6.||Berkhof, J: 2 articles (10/2007 - 03/2007)|
|7.||Bruynzeel, Anna M E: 2 articles (09/2007 - 01/2007)|
|8.||van der Vijgh, Wim J F: 2 articles (09/2007 - 11/2004)|
|9.||Abou El Hassan, M A: 2 articles (03/2007 - 02/2007)|
|10.||Dhar, Dipok K: 1 article (07/2012)|
06/28/2004 - "Sustained protective effects of 7-monohydroxyethylrutoside in an in vivo model of cardiac ischemia-reperfusion."
06/28/2004 - "In this study, we investigated potential sustained cardioprotective effects of monoHER in a model of ischemia-reperfusion (I/R) in mice. "
06/28/2004 - "MonoHER (500 mg/kg) was given intraperitoneally (i.p.) one hour before ischemia. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
02/12/2007 - "To obtain more insight in the mechanism underlying the selective protective effects of monoHER, we investigated whether monoHER (1 mM) affects DOX-induced apoptosis in neonatal rat cardiac myocytes (NeRCaMs), human endothelial cells (HUVECs) and the ovarian cancer cell lines A2780 and OVCAR-3. "
|3.||Dehydration (Water Stress)
11/01/2004 - "Significant erythrocyte oxidant damage at baseline was indicated by: (i) dehydration, reduced cell K content, and up-regulated K-Cl co-transport; (ii) marked membrane externalization of phosphatidylserine; (iii) reduced plasma and membrane content of vitamin E; and (iv) increased membrane bound IgG. MonoHER treatment increased erythrocyte K content, and markedly improved all cellular indicators of oxidant stress and of lipid membrane peroxidation. "
01/01/2007 - "A subsequent clinical phase I study showed that an i.v. dose of 1,500mg/m2 is a feasible and safe dose to be evaluated in a phase II study to investigate the protective properties of monoHER against doxorubicin-induced cardiotoxicity in cancer patients."
05/01/2006 - "Thus, 1,500 mg/m(2) is a feasible and safe dose to be evaluated in a phase II study to investigate the protective properties of monoHER against doxorubicin-induced cardiotoxicity in cancer patients."
05/01/2006 - "In the present phase I study, the possible side effects and the pharmacokinetics of monoHER were evaluated in healthy volunteers with the aim to develop a safe and feasible dose to be evaluated in cancer patients treated with doxorubicin. "
10/22/2007 - "Eight patients with metastatic cancer were treated with DOX preceded by a 10 min i.v. infusion of 1500 mg m(-2) monoHER. "
02/01/2011 - "These results suggest that reduction of doxorubicin-induced NF-κB activation by monoHER, which sensitises cancer cells to apoptosis, is involved in the chemosensitising effect of monoHER in human liposarcoma cells."
|3.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|5.||Immunoglobulin G (IgG)
|9.||Glutathione (Reduced Glutathione)
|10.||Anti-Inflammatory Agents (Anti-Inflammatories)